Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high-definition picture?

Pulm Circ. 2021 May 29;11(2):20458940211018074. doi: 10.1177/20458940211018074. eCollection 2021 Apr-Jun.

Lucilla Piccari¹, Roberto J Bernardo², Diego Rodríguez-Chiaradía^{1

3

4}, Patrizio Vitulo^{5

6}, S John Wort⁷, Sandeep Sahay^{8

9}

¹ Department of Pulmonary Medicine, Hospital del Mar, Barcelona, Spain.
² Division of Pulmonary, Critical Care and Sleep Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
³ Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), Madrid, Spain.
⁴ University Pompeu Fabra, Barcelona, Spain.
⁵ Department of Pulmonary Medicine, IRCCS Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy.
⁶ Italian Pulmonary Hypertension Network, IPHNET, Rome, Italy.
⁷ Department of Pulmonary Medicine, National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK.
⁸ Weill Cornell Medicine, New York, NY, USA.
⁹ Division of Pulmonary Critical Care and Sleep Medicine, Houston Methodist Hospital, Houston, TX, USA.

No abstract available